Compare Repligen Corporation Common Stock (RGEN) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs VNET Group Inc — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while VNET Group Inc trades at $4.54 (market cap $1.49B). The key difference: Repligen Corporation Common Stock is far larger — about 7.5× VNET Group Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and VNET Group Inc for 16 Days on average.
| RGEN | VNET | |
|---|---|---|
Market Cap | $11.14B | $1.49B |
Volume | 1,259,263 | 3,619,133 |
Sector | Health | Technology |
52-Week High | $194.57 | $14.03 |
52-Week Low | $102.87 | $4.49 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $11.02B | $5.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VNET trades at $5.26, down 1.13% today, and has hit new 52-week lows recently. The technical outlook is bearish, with moving averages signaling a downtrend. Fundamentally, the company reported a net loss of $256.77 million in 2025, with a negative net income margin of -22.18%, though revenue grew to $9.95 billion. Recent news includes a strategic investment closing and a cooperation agreement with CATL, providing some positive catalysts amid financial challenges.
The outlook remains cautious due to persistent losses and high leverage, but analyst sentiment is moderately positive with a 'Buy' consensus. Key risks include balance sheet strain and competitive pressures in the data center market. Investment opportunity hinges on execution of growth initiatives and improvement in profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
